NCT07433660

Brief Summary

Cancer affects millions of people worldwide and can significantly impact not only survival, but also day-to-day quality of life. Treatments such as surgery, chemotherapy, and radiation can cause side effects like fatigue, pain, and neuropathy, which may affect physical function, emotional well-being, and social relationships. While many studies have examined factors that influence quality of life; such as age, type and stage of cancer, and treatment-related symptoms; there is still a need for tools that more fully reflect patients' lived experiences. This study aims to develop and implement a patient-centered quality of life (QOL) survey designed specifically for individuals with cancer. By directly involving patients in sharing what matters most to them, the survey seeks to provide a more complete and accurate understanding of how cancer and its treatment affect daily life. The results will help patients, families, and healthcare providers better identify needs, guide supportive care, and improve overall well-being throughout the cancer journey.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
67mo left

Started Feb 2026

Longer than P75 for all trials

Geographic Reach
1 country

5 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress6%
Feb 2026Dec 2031

Study Start

First participant enrolled

February 1, 2026

Completed
18 days until next milestone

First Submitted

Initial submission to the registry

February 19, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 25, 2026

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2031

Expected
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2031

Last Updated

March 2, 2026

Status Verified

February 1, 2026

Enrollment Period

5 years

First QC Date

February 19, 2026

Last Update Submit

February 26, 2026

Conditions

Cancer (Solid Tumors)Cancer (With or Without Metastasis)Cancer - OvarianCancer AbdomenCancer (Advanced Stage)Cancer (Active Cancer, Meaning Not Being Cancer Free), of Any Stage and Involving Any Treatment/Care Regimen; i.e. Curative, Life-extending, or Palliative

Keywords

CancerQuality of LifeQOLRegistryPatient

Outcome Measures

Primary Outcomes (1)

  • Quality of Life Differences based on Race or Ethnicity or Gender

    Quality of Life Differences based on Race or Ethnicity or Gender based on Quality-of-life questionnaire. We will look for changes in each question on Quality-of-life from baseline to 6-12-18-24 months.

    Baseline, 6-12-18-24 months

Study Arms (1)

Patients Diagnosed with primary cancer in past 6 months

Patients Diagnosed with primary cancer in past 6 months will be divided into Race, ethnicity and gender and will be looked for differences in quality of life based on these subsets.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Newly diagnosed with a- primary cancer within the past six months from WellSpan cancer centers.

You may qualify if:

  • Age 18 years and above
  • Primary cancer diagnosis (newly diagnosed within the past 6 months)
  • Able to sign informed consent.

You may not qualify if:

  • Patients with age\<18 years,
  • Patients with primary non-melanoma skin, neurological malignancies (Brain or brain metastases), and primary hematological malignancies.
  • Patients with severe cognitive impairment, unable to sign informed consent or unable to complete quality of life questionnaire.
  • Patients with life expectancy of \<90 days, in the opinion of treating investigator.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

WellSpan Medical Oncology & Hematology

Chambersburg, Pennsylvania, 17201, United States

RECRUITING

WellSpan Ephrata Cancer Center

Ephrata, Pennsylvania, 17522, United States

RECRUITING

WellSpan Adams Cancer Center

Gettysburg, Pennsylvania, 17325, United States

RECRUITING

WellSpan Sechler Family Cancer Center

Lebanon, Pennsylvania, 17042, United States

RECRUITING

WellSpan York Cancer Center

York, Pennsylvania, 17403, United States

RECRUITING

Related Publications (5)

  • Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993 Mar;11(3):570-9. doi: 10.1200/JCO.1993.11.3.570.

    PMID: 8445433BACKGROUND

  • Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum. 2001 Apr;28(3):465-70.

    PMID: 11338755BACKGROUND

  • Yennurajalingam S, Rodrigues LF, Shamieh O, Tricou C, Filbet M, Naing K, Ramaswamy A, Perez-Cruz PE, Bautista MJS, Bunge S, Muckaden MA, Sewram V, Fakrooden S, Noguera-Tejedor A, Rao SS, Liu D, Park M, Williams JL, Lu Z, Cantu H, Hui D, Reddy SK, Bruera E. Perception of Curability Among Advanced Cancer Patients: An International Collaborative Study. Oncologist. 2018 Apr;23(4):501-506. doi: 10.1634/theoncologist.2017-0264. Epub 2017 Nov 20.

    PMID: 29158371BACKGROUND

  • Grabner M, Molife C, Wang L, Winfree KB, Cui ZL, Cuyun Carter G, Hess LM. Data Integration to Improve Real-world Health Outcomes Research for Non-Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration. JMIR Cancer. 2021 Apr 12;7(2):e23161. doi: 10.2196/23161.

    PMID: 33843600BACKGROUND

  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.

    PMID: 33538338BACKGROUND

MeSH Terms

Conditions

NeoplasmsOvarian Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal Disorders

Study Officials

  • Navesh Sharma, DO, PhD, FACRO

    WellSpan Health

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Joan K Moore, MSN, RN, OCN, CCRP

CONTACT

717-741-8124jmoore@wellspan.org

Rahul Kashyap, MBBS, MBA, FCCM

CONTACT

717-851-4611rkashyap@wellspan.org

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
24 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Medical Director Research

Study Record Dates

First Submitted

February 19, 2026

First Posted

February 25, 2026

Study Start

February 1, 2026

Primary Completion (Estimated)

February 1, 2031

Study Completion (Estimated)

December 1, 2031

Last Updated

March 2, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

We don't have patient and institution permission to share individual participant data (IPD).

Locations

US(5)